Bolt Biotherapeutics, Inc. (BOLT)
Nasdaq · Healthcare · Biotechnology
$3.50+1.42%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $6.7M
- 52-week range
- $3.10 – $7.20
- 52-week change
- −44.35%
- EPS (trailing)
- −$16.51
Fiscal year to Dec 2025
- Revenue
- $7.7M (+0.07%)
- Net income
- −$33.4M
- Operating margin
- −469.3%
- Diluted EPS
- −$17.85
- Free cash flow
- −$39.9M
From the company’s annual report on SEC EDGAR.
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc.
Headquarters: Redwood City, United States · 23 employees · boltbio.com